BioBlog

The Democrats unveiled their plan to combat rising drug prices. House Leader Nancy Pelosi’s plan would lift the ban on the HHS to allow the secretary to negotiate Medicare drug prices. Pharmaceutical companies would be forced to comply or face stiff penalties. Other top stories this week focus on

In this week’s Innovation Partners’ BioBlog, states consider several models for value-based drug pricing but face significant challenges to move forward with any of them. A House panel is investigating the role that private equity firms may play in surprise patient billing; many of these firms own

In this week’s Innovation Partners BioBlog, we feature several stories on the continuing healthcare debate. The President promises a new healthcare plan, but any plan promises to be contentious to some on either side of the aisle. New CPT codes were announced for 2020 that include e-visits and

The Centers for Medicare and Medicaid Services launched a brand-new, redesigned site to help the 60 million eligible for Part D coverage and Medicare Advantage to comparison shop their plans. New research in cancer offers the potential for breakthroughs in non-small-cell lung cancer. MedCo’s new

In this week’s Innovation Partners BioBlog, we take a look at a new report from Accenture Life Sciences which indicates that patients prefer to turn to patient groups rather than pharmaceutical companies for resources and information. This may indicate a potential opportunity for pharmaceutical

Tufts Health Plan and Harvard Pilgrim announced a planned merger, which would make the new as-yet-to-be-named organization a rising competitor to the Partners Health Group, a dominant player in the area. CMS will display the 5-star rating next to plans on the Affordable Care website, a move to make

In this week’s Innovation Partners BioBlog, all eyes are on the pharmaceutical industry. The new Medicare coverage rules for CAR-T therapy may pave the way for adoption of more slow-growing meds. The FDA weighs criminal and civil charges against a subsidiary of Novartis for falsely reporting data.

In this week’s Innovation Partners BioBlog, we look at the many changes and updates in the pharmaceutical world. The Senate’s drug pricing provision is raising alarms for some doctors. Canadian hospitals face a shortage of critical chemotherapy drugs. Eli Lilly’s CEO pushed back at Democratic party